Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and ...

个体化治疗策略：选择最佳 CDK4/6i 随着乳腺癌治疗进入 「 慢病管理时代 」，我们的目标是帮助晚期乳腺癌患者实现更长久、更优质的生存。

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor ...

Opens in a new tab or window Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival if they continued CDK4/6 inhibition plus ...

Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.

SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...